Let's gather to discuss:
- How do we incorporate peri-operative systemic therapy with local treatment for MIBC?
- Do new adjuvant and refractory treatments affect first-line management of RCC?
- How will genetic and molecular profiles guide management of mAPMN/S?
Email dann.george@duke.edu to RSVP.
